You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCefaclor
Accession NumberDB00833  (APRD00243)
TypeSmall Molecule
GroupsApproved
DescriptionSemisynthetic, broad-spectrum antibiotic derivative of cephalexin. [PubChem]
Structure
Thumb
Synonyms
3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid
CCL
Cefaclor
Cefaclor
Cefaclor
Cefaclor anhydrous
Cefacloro
Cefaclorum
Céfeaclor
Cephaclor
External Identifiers
  • Compound 99638
  • S 6472
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CeclorPowder, for suspension250 mgOralPendopharm Division Of De Pharmascience Inc1980-12-312016-10-25Canada
CeclorPowder, for suspension375 mgOralPendopharm Division Of De Pharmascience Inc1990-12-312016-10-25Canada
CeclorCapsule250 mgOralPendopharm Division Of De Pharmascience Inc1980-12-312016-10-25Canada
CeclorCapsule500 mgOralPendopharm Division Of De Pharmascience Inc1980-12-312016-10-25Canada
CeclorPowder, for suspension125 mgOralPendopharm Division Of De Pharmascience Inc1980-12-312016-10-25Canada
CefaclorSuspension125 mgOralMm Therapeutics Inc1998-06-112009-12-18Canada
CefaclorSuspension250 mgOralMm Therapeutics Inc1998-06-042009-12-18Canada
CefaclorCapsule250 mgOralMm Therapeutics Inc1998-06-042009-12-18Canada
CefaclorSuspension375 mgOralMm Therapeutics Inc1998-06-042009-12-18Canada
CefaclorCapsule500 mgOralMm Therapeutics Inc1998-06-042009-12-18Canada
Cefaclor CapsulesCapsule250 mgOralIvax Pharmaceuticals Incorporated1998-07-14Not applicableCanada
Cefaclor CapsulesCapsule500 mgOralIvax Pharmaceuticals Incorporated1998-07-14Not applicableCanada
Cefaclor SuspensionPowder, for suspension375 mgOralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Cefaclor SuspensionPowder, for suspension125 mgOralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Cefaclor SuspensionPowder, for suspension187 mgOralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Cefaclor SuspensionPowder, for suspension250 mgOralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Cefaclor-125Powder125 mgOralPro Doc Limitee1998-11-242009-07-23Canada
Cefaclor-250Powder250 mgOralPro Doc Limitee1998-11-242009-07-23Canada
Cefaclor-250Capsule250 mgOralPro Doc Limitee1998-11-232009-07-23Canada
Cefaclor-375Powder375 mgOralPro Doc Limitee1998-11-242009-07-23Canada
Cefaclor-500Capsule500 mgOralPro Doc Limitee1998-11-232009-07-23Canada
Dom-cefaclor 125 - Sus 25mg/mlSuspension25 mgOralDominion Pharmacal1998-03-202010-01-19Canada
Dom-cefaclor 250-sus 50mg/mlSuspension50 mgOralDominion Pharmacal1998-03-202010-01-19Canada
Dom-cefaclor 375 B.I.D.Suspension75 mgOralDominion Pharmacal1998-03-202010-01-19Canada
Novo-cefaclorCapsule250 mgOralTeva Canada Limited1999-06-04Not applicableCanada
Novo-cefaclorCapsule500 mgOralTeva Canada Limited1999-06-04Not applicableCanada
Nu-cefaclorPowder125 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-cefaclorCapsule500 mgOralNu Pharm Inc1998-03-182012-09-04Canada
Nu-cefaclorPowder250 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-cefaclorPowder375 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-cefaclor Capsules 250mgCapsule250 mgOralNu Pharm Inc1998-03-182012-09-04Canada
PMS-cefaclorCapsule250 mgOralPharmascience Inc1997-01-172016-10-28Canada
PMS-cefaclorCapsule500 mgOralPharmascience Inc1997-01-172016-10-28Canada
PMS-cefaclor 125 - Pws 25mg/mlPowder, for solution25 mgOralPharmascience Inc1998-03-092016-10-28Canada
PMS-cefaclor 250 - Pws 50mg/mlPowder, for solution50 mgOralPharmascience Inc1998-03-092016-10-28Canada
PMS-cefaclor 375 B.I.D.Powder, for solution75 mgOralPharmascience Inc1998-03-092016-10-28Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cefaclorCapsule500 mgOralApotex Inc1997-01-20Not applicableCanada
Apo-cefaclorPowder125 mgOralApotex Inc1998-03-06Not applicableCanada
Apo-cefaclorPowder250 mgOralApotex Inc1998-03-06Not applicableCanada
Apo-cefaclorCapsule250 mgOralApotex Inc1997-01-20Not applicableCanada
Apo-cefaclorPowder375 mgOralApotex Inc1998-03-06Not applicableCanada
CefaclorSuspension250 mg/5mLOralRebel Distributors Corp1997-10-02Not applicableUs
CefaclorTablet, film coated, extended release500 mg/1OralTeva Pharmaceuticals USA Inc2002-09-26Not applicableUs
CefaclorCapsule500 mg/1OralJazeera Pharmaceutical2007-03-04Not applicableUs
CefaclorSuspension125 mg/5mLOralCarlsbad Technology, Inc.2012-03-27Not applicableUs
CefaclorCapsule250 mg/1OralPhysicians Total Care, Inc.1996-01-24Not applicableUs
CefaclorCapsule250 mg/1OralA S Medication Solutions2007-05-01Not applicableUs
CefaclorCapsule250 mg/1Oralbryant ranch prepack2009-11-06Not applicableUs
CefaclorSuspension125 mg/5mLOralPACK Pharmaceuticals, LLC2012-10-25Not applicableUs
CefaclorCapsule500 mg/1OralPd Rx Pharmaceuticals, Inc.2007-05-01Not applicableUs
CefaclorFor suspension125 mg/5mLOralFsc Laboratories, Inc.2015-10-26Not applicableUs
CefaclorCapsule250 mg/1OralJazeera Pharmaceutical2007-03-04Not applicableUs
CefaclorSuspension187 mg/5mLOralCarlsbad Technology, Inc.2012-03-27Not applicableUs
CefaclorCapsule500 mg/1OralPhysicians Total Care, Inc.1995-04-05Not applicableUs
CefaclorCapsule500 mg/1OralA S Medication Solutions2007-05-01Not applicableUs
CefaclorSuspension250 mg/5mLOralPACK Pharmaceuticals, LLC2012-10-31Not applicableUs
CefaclorCapsule250 mg/1Oralbryant ranch prepack2007-05-01Not applicableUs
CefaclorCapsule250 mg/1OralAlvogen, Inc.2010-01-18Not applicableUs
CefaclorFor suspension250 mg/5mLOralFsc Laboratories, Inc.2015-10-26Not applicableUs
CefaclorCapsule250 mg/1OralWest Ward Pharmaceuticals Corp2007-05-01Not applicableUs
CefaclorSuspension250 mg/5mLOralCarlsbad Technology, Inc.2012-03-27Not applicableUs
CefaclorCapsule250 mg/1OralCarlsbad Technology, Inc.2008-07-31Not applicableUs
CefaclorCapsule500 mg/1OralA S Medication Solutions2007-05-01Not applicableUs
CefaclorSuspension375 mg/5mLOralPACK Pharmaceuticals, LLC2012-10-31Not applicableUs
CefaclorCapsule500 mg/1OralAlvogen, Inc.2010-01-18Not applicableUs
CefaclorFor suspension375 mg/5mLOralFsc Laboratories, Inc.2015-10-26Not applicableUs
CefaclorCapsule500 mg/1OralWest Ward Pharmaceuticals Corp2007-05-01Not applicableUs
CefaclorSuspension375 mg/5mLOralCarlsbad Technology, Inc.2012-03-27Not applicableUs
CefaclorCapsule500 mg/1OralCarlsbad Technology, Inc.2008-07-31Not applicableUs
CefaclorCapsule500 mg/1OralA S Medication Solutions2008-07-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlenfralChoseido Pharmaceutical
AlfacetGalenika
AlfatilDexo
Alfatil LPDexo
Ceclor CDLilly
DistaclorFlynn
KeflorAlphapharm
KefralShionogi Seiyaku
PanacefValeas
PanoralEberth
RaniclorRanbaxy Pharmaceuticals Inc.
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Cefaclor monohydrate
70356-03-5
Thumb
  • InChI Key: WKJGTOYAEQDNIA-IOOZKYRYSA-N
  • Monoisotopic Mass: 385.0499195
  • Average Mass: 385.82
DBSALT001804
Categories
UNII3Z6FS3IK0K
CAS number53994-73-3
WeightAverage: 367.807
Monoisotopic: 367.039354348
Chemical FormulaC15H14ClN3O4S
InChI KeyQYIYFLOTGYLRGG-GPCCPHFNSA-N
InChI
InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1
IUPAC Name
(6R,7R)-7-[(2R)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][C@]12SCC(Cl)=C(N1C(=O)[[email protected]]2NC(=O)[[email protected]](N)C1=CC=CC=C1)C(O)=O
Pharmacology
IndicationFor the treatment of certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections.
Structured Indications
PharmacodynamicsCefaclor is a second generation cephalosporin antibiotic with a spectrum resembling first-generation cephalosporins. In vitro tests demonstrate that the bactericidal action of the cephalosporins results from inhibition of cell-wall synthesis. Cefaclor has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections: Gram positive aerobes - Staphylococci (including coagulase-positive, coagulase-negative, and penicillinase-producing strains), Streptococcus pneumoniae, and Streptococcus pyogenes (group A ß-hemolytic streptococci). Gram-negative aerobes - Escherichia coli, Haemophilus influenzae (including ß-lactamase-producing ampicillin-resistant strains), Klebsiella sp, and Proteus mirabilis.
Mechanism of actionCefaclor, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. It is possible that cefaclor interferes with an autolysin inhibitor.
TargetKindPharmacological actionActionsOrganismUniProt ID
Penicillin-binding protein 3Proteinyes
inhibitor
Streptococcus pneumoniaeQ75Y35 details
Penicillin-binding protein 1AProteinyes
inhibitor
Clostridium perfringens (strain 13 / Type A)Q8XJ01 details
Related Articles
AbsorptionWell absorbed after oral administration, independent of food intake.
Volume of distributionNot Available
Protein binding23.5%
Metabolism

No appreciable biotransformation in liver (approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours).

Route of eliminationApproximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours.
Half life0.6-0.9 hour
ClearanceNot Available
ToxicitySymptoms of overdose include diarrhea, nausea, stomach upset, and vomiting.
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcenocoumarolCefaclor may increase the anticoagulant activities of Acenocoumarol.Approved
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Cefaclor.Investigational
DicoumarolCefaclor may increase the anticoagulant activities of Dicoumarol.Approved
Ethyl biscoumacetateCefaclor may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FluindioneCefaclor may increase the anticoagulant activities of Fluindione.Investigational
PhenindioneCefaclor may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonCefaclor may increase the anticoagulant activities of Phenprocoumon.Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefaclor.Approved
ProbenecidThe serum concentration of Cefaclor can be increased when it is combined with Probenecid.Approved
WarfarinCefaclor may increase the anticoagulant activities of Warfarin.Approved
Food Interactions
  • Preferably on an empty stomach, not really problematic.
References
Synthesis Reference

Bing L. Wong, Yong-Qiang Shen, Yung-Pin Chen, “Enzymatic production of cefaclor from cephalexin.” U.S. Patent US5939299, issued November, 1987.

US5939299
General References
  1. Hebert AA, Sigman ES, Levy ML: Serum sickness-like reactions from cefaclor in children. J Am Acad Dermatol. 1991 Nov;25(5 Pt 1):805-8. [PubMed:1802903 ]
  2. Parra FM, Igea JM, Martin JA, Alonso MD, Lezaun A, Sainz T: Serum sickness-like syndrome associated with cefaclor therapy. Allergy. 1992 Aug;47(4 Pt 2):439-40. [PubMed:1456417 ]
External Links
ATC CodesJ01DC04
AHFS Codes
  • 08:12.06.08
PDB EntriesNot Available
FDA labelDownload (186 KB)
MSDSDownload (43.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8839
Blood Brain Barrier-0.9817
Caco-2 permeable-0.8239
P-glycoprotein substrateSubstrate0.6569
P-glycoprotein inhibitor INon-inhibitor0.9413
P-glycoprotein inhibitor IINon-inhibitor0.9955
Renal organic cation transporterNon-inhibitor0.9369
CYP450 2C9 substrateNon-substrate0.8314
CYP450 2D6 substrateNon-substrate0.8361
CYP450 3A4 substrateNon-substrate0.5597
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9236
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9193
Ames testNon AMES toxic0.6676
CarcinogenicityNon-carcinogens0.8489
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.2960 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9966
hERG inhibition (predictor II)Non-inhibitor0.85
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
  • Ceph international corp
  • Clonmel healthcare ltd
  • Hikma pharmaceuticals
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Marsam pharmaceuticals llc
  • Ranbaxy pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Yung shin pharmaceutical industrial co ltd
  • Acs dobfar info sa
  • Ranbaxy laboratories ltd
  • World gen llc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral250 mg
CapsuleOral500 mg
PowderOral125 mg
PowderOral250 mg
PowderOral375 mg
CapsuleOral250 mg/1
CapsuleOral500 mg/1
For suspensionOral125 mg/5mL
For suspensionOral250 mg/5mL
For suspensionOral375 mg/5mL
SuspensionOral125 mg/5mL
SuspensionOral125 mg
SuspensionOral187 mg/5mL
SuspensionOral250 mg/5mL
SuspensionOral250 mg
SuspensionOral375 mg/5mL
SuspensionOral375 mg
Tablet, film coated, extended releaseOral500 mg/1
Powder, for suspensionOral125 mg
Powder, for suspensionOral187 mg
Powder, for suspensionOral250 mg
Powder, for suspensionOral375 mg
SuspensionOral25 mg
SuspensionOral50 mg
SuspensionOral75 mg
Powder, for solutionOral25 mg
Powder, for solutionOral50 mg
Powder, for solutionOral75 mg
Prices
Unit descriptionCostUnit
Ceclor 15 500 mg capsule Bottle70.0USD bottle
Ceclor 375 mg/5ml Suspension 100ml Bottle59.99USD bottle
Ceclor 250 mg/5ml Suspension 150ml Bottle58.98USD bottle
Cefaclor 250 mg/5ml Suspension 150ml Bottle53.87USD bottle
Cefaclor 375 mg/5ml Suspension 100ml Bottle53.87USD bottle
Ceclor 15 250 mg capsule Bottle38.0USD bottle
Ceclor 125 mg/5ml Suspension 150ml Bottle34.99USD bottle
Ceclor 187 mg/5ml Suspension 100ml Bottle34.99USD bottle
Ceclor 250 mg/5ml Suspension 75ml Bottle31.99USD bottle
Cefaclor 125 mg/5ml Suspension 150ml Bottle29.41USD bottle
Cefaclor 250 mg/5ml Suspension 75ml Bottle29.37USD bottle
Cefaclor 187 mg/5ml Suspension 100ml Bottle29.26USD bottle
Cefaclor 375 mg/5ml Suspension 50ml Bottle27.44USD bottle
Cefaclor 187 mg/5ml Suspension 50ml Bottle14.92USD bottle
Cefaclor 125 mg/5ml Suspension 75ml Bottle14.7USD bottle
Ceclor 500 mg pulvule5.69USD each
Cefaclor 500 mg capsule4.05USD capsule
Cefaclor CR 500 mg 12 Hour tablet3.79USD tablet
Ceclor 250 mg pulvule3.28USD each
Raniclor 375 mg chewable tablet2.98USD tablet
Cefaclor 250 mg capsule2.07USD capsule
Raniclor 250 mg chewable tablet1.99USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point327 °CNot Available
water solubility1E+004 mg/LYALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.21 mg/mLALOGPS
logP0.85ALOGPS
logP-2.3ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)3.03ChemAxon
pKa (Strongest Basic)7.44ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area112.73 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity89.56 m3·mol-1ChemAxon
Polarizability35.11 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassLactams
Sub ClassBeta lactams
Direct ParentCephalosporins
Alternative Parents
Substituents
  • Cephalosporin
  • N-acyl-alpha amino acid or derivatives
  • Alpha-amino acid amide
  • Phenylacetamide
  • Alpha-amino acid or derivatives
  • Aralkylamine
  • Benzenoid
  • Monocyclic benzene moiety
  • Meta-thiazine
  • Vinylogous halide
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azetidine
  • Azacycle
  • Chloroalkene
  • Haloalkene
  • Dialkylthioether
  • Vinyl halide
  • Vinyl chloride
  • Hemithioaminal
  • Thioether
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Streptococcus pneumoniae
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function:
Not Available
Gene Name:
pbp3
Uniprot ID:
Q75Y35
Molecular Weight:
45209.84 Da
References
  1. Chambers HF, Miick C: Characterization of penicillin-binding protein 2 of Staphylococcus aureus: deacylation reaction and identification of two penicillin-binding peptides. Antimicrob Agents Chemother. 1992 Mar;36(3):656-61. [PubMed:1622180 ]
Kind
Protein
Organism
Clostridium perfringens (strain 13 / Type A)
Pharmacological action
yes
Actions
inhibitor
General Function:
Transferase activity, transferring glycosyl groups
Specific Function:
Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits) (By similarity).
Gene Name:
pbpA
Uniprot ID:
Q8XJ01
Molecular Weight:
75176.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chambers HF, Miick C: Characterization of penicillin-binding protein 2 of Staphylococcus aureus: deacylation reaction and identification of two penicillin-binding peptides. Antimicrob Agents Chemother. 1992 Mar;36(3):656-61. [PubMed:1622180 ]
  4. Li M, Anderson GD, Phillips BR, Kong W, Shen DD, Wang J: Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55. Epub 2006 Jan 24. [PubMed:16434549 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Molecular Weight:
83867.71 Da
References
  1. Zuccotti G, Dauria E, Torcoletti M, Lodi F, Bernardo L, Riva E: Clinical and pro-host effects of cefaclor in prophylaxis of recurrent otitis media in HIV-infected children. J Int Med Res. 2001 Jul-Aug;29(4):349-54. [PubMed:11675909 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, Amidon GL: CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999 Mar;88(3):347-50. [PubMed:10052994 ]
  2. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297 ]
  3. Li M, Anderson GD, Phillips BR, Kong W, Shen DD, Wang J: Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55. Epub 2006 Jan 24. [PubMed:16434549 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297 ]
  2. Li M, Anderson GD, Phillips BR, Kong W, Shen DD, Wang J: Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55. Epub 2006 Jan 24. [PubMed:16434549 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23